Gabapentin for the treatment of behavioral and psychological symptoms of dementia

Journals Menu

Follow SCIRP

ISSN Print: 2169-2459
ISSN Online: 2169-2467
www.scirp.org/journal/aad
E-mail: aad@scirp.org

"Gabapentin for the treatment of behavioral and psychological symptoms of dementia"
written by Rajesh R. Tampi, Banu Ozkan, Deena Williamson,
published by Advances in Alzheimer's Disease, Vol.1 No.2, 2012

has been cited by the following article(s):

[1]	When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative
	2019

[2]	Cost-effectiveness of atypical antipsychotics for the treatment of dementia in Thailand
	2019

[3]	Efficacy and cost of atypical antipsychotics in treatment and management of dementia
	2015

[4]	ИСПОЛЬЗОВАНИЕ ГАБАПЕНТИНА (МЕДИТАНА) В КЛИНИЧЕСКОЙ ПРАКТИКЕ НЕВРОЛОГА С ПОЗИЦИЙ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ
	2014

[5]	USE OF GABAPENTIN (MEDITAN®) IN NEUROLOGIST'S CLINICAL PRACTICE FROM THE PERSPECTIVE OF EVIDENTIARY MEDICINE
	2014

[6]	Використання габапентину (Медітану) в клінічній практиці невролога з позиції доказової медицини
	2014

[7]	Use of Gabapentin (Meditan) in Clinical Practice of Neurologist from the Standpoint of Evidence-Based Medicine
	2014

Follow SCIRP

[1]	A randomized, double-blind, placebo-controlled clinical trial to evaluate pregabalin efficacy in the treatment of behavioral and psychological symptoms of dementia in patients with Alzheimer’s disease Frontiers in Neuroscience, 2024 DOI:10.3389/fnins.2024.1460325

[2]	When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative Journal of the American Medical Directors Association, 2019 DOI:10.1016/j.jamda.2019.05.022